Cellmid Limited (ASX:CDY) is a biotechnology company listed on the Australian Stock Exchange. The company is committed to the commercialization of its technology portfolio around midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.
CDY holds the largest and most comprehensive intellectual property portfolio globally in relation to midkine, a validated therapeutic and diagnostic target in inflammation and cancer.
CDY is actively looking for partners to commercialise the Company’s significant midkine intellectual property assets in ischemia, cancer and autoimmune diseases. In addition CDY’s broad cancer marker patents are also available for licensing.
Preclinical Study Shows Reduction in Disease Severity
• Cellmid has recently completed in vivo testing of two of its anti-midkine antibodies
• Both antibodies decreased disease severity in an animal model of multiple sclerosis
• Key mechanisms of actions have been demonstrated
Cellmid and Pacific Edge Sign Cancer Diagnostic License
Sydney, 19 May 2010 - Cellmid Limited (ASX:CDY) and Pacific Edge Biotechnology Limited (PEB), have entered into a non-exclusive license agreement for the use of CDY’s midkine technology in PEB’s bladder cancer test.
Cellmid will receive upfront and milestone payments in addition to royalties on product sales.
